The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Dec. 31, 2019
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Tereza Moore, Palo Alto, CA (US);

Tina M. Cowan, Palo Alto, CA (US);

Gregory M. Enns, Palo Alto, CA (US);

Mehrdad Shamloo, Stanford, CA (US);

Michael J. Green, Half Moon Bay, CA (US);

Alam Jahangir, San Jose, CA (US);

Rolando E. Yanes, Santa Clara, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 31/05 (2006.01); A61K 31/155 (2006.01); A61K 31/194 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4155 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/433 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/505 (2006.01); A61K 31/618 (2006.01); A61K 31/706 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 31/05 (2013.01); A61K 31/155 (2013.01); A61K 31/194 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4155 (2013.01); A61K 31/422 (2013.01); A61K 31/4245 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/4365 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/505 (2013.01); A61K 31/618 (2013.01); A61K 31/706 (2013.01);
Abstract

Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions.


Find Patent Forward Citations

Loading…